Milvexian

Jefferies upgraded Bristol Myers to Buy from Hold with a price target of $70, up from $63. The firm believes Cobenfy can become a $10B-plus drug and is increasingly confident in Milvexian's non-inferiority. They see an EPS trough in 2029 or earlier with operating leverage.

Bristol Myers Squibb announced CHMP's recommendation for repotrectinib approval for ROS1-positive advanced NSCLC and certain solid tumors, under EC review for Jan 2025 decision. Based on TRIDENT-1 and CARE trials, repotrectinib showed meaningful response rates and durable activity, with manageable safety profile. Previously approved in the U.S., repotrectinib targets ROS1 and NTRK fusions in advanced solid tumors. Bristol-Myers Squibb also saw analyst upgrades, FDA approval for Cobenfy, and acquisition of Karuna Therapeutics for growth portfolio expansion.

RUH Bath NHS Foundation Trust seeks volunteers for Librexia study on Milvexian, an anticoagulant to reduce ischaemic stroke risk. Participants must be 40+ and have attended RUH within 48 hours of stroke or TIA. Milvexian thins blood to prevent clots, with patients randomly assigned to receive it or a placebo, in addition to standard meds. Regular assessments at RUH are required.

The 'Atrial Fibrillation - Pipeline Insight, 2024' report by ResearchAndMarkets.com provides insights on 12+ companies and 12+ pipeline drugs, including Milvexian (Bristol-Myers Squibb), Etripamil (Milestone Pharmaceuticals), and AP31969 (Acesion Pharma). The report covers clinical and nonclinical stage products, therapeutics assessment, and pipeline development activities.

September 2024 saw significant developments in cardiology, including the ESC Congress 2024 and FDA approvals like plozasiran for familial chylomicronemia syndrome. Edgewise Therapeutics reported positive data for EDG-7500 in hypertrophic cardiomyopathy. ESC Congress 2024 featured 4,400 abstracts and 32,000 attendees, highlighting new data on finerenone, milvexian, and aficamten. The Family Heart Global Summit in Dallas also provided insights on lipoprotein(a) therapies. The APAC Recap series, a collaboration with the Academy of Physician Associates in Cardiology, shared key takeaways from medical meetings.

BMO Capital raised Bristol-Myers Squibb's price target to $53.00 from $48.00, maintaining a Market Perform rating, following the approval of COBENFY, priced at $1,850/30-day supply. Analysts project COBENFY could reach peak sales of $2.4 billion for Schizophrenia and $3.9 billion for Alzheimer's psychosis, reflecting a more optimistic outlook for the company's financial performance.